ITRM920165A1 - Impiego di l-carnitina nel trattamento di pazienti hiv-sieropositivi presentanti deficit di carnitina. - Google Patents

Impiego di l-carnitina nel trattamento di pazienti hiv-sieropositivi presentanti deficit di carnitina.

Info

Publication number
ITRM920165A1
ITRM920165A1 IT000165A ITRM920165A ITRM920165A1 IT RM920165 A1 ITRM920165 A1 IT RM920165A1 IT 000165 A IT000165 A IT 000165A IT RM920165 A ITRM920165 A IT RM920165A IT RM920165 A1 ITRM920165 A1 IT RM920165A1
Authority
IT
Italy
Prior art keywords
carnitine
deficit
hiv
treatment
patients presenting
Prior art date
Application number
IT000165A
Other languages
English (en)
Inventor
Simone Claudio De
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Priority to ITRM920165A priority Critical patent/IT1255039B/it
Publication of ITRM920165A0 publication Critical patent/ITRM920165A0/it
Priority to EP93103740A priority patent/EP0560275A1/en
Priority to ZA931700A priority patent/ZA931700B/xx
Priority to KR1019930003612A priority patent/KR0148350B1/ko
Priority to JP5050584A priority patent/JPH069387A/ja
Publication of ITRM920165A1 publication Critical patent/ITRM920165A1/it
Application granted granted Critical
Publication of IT1255039B publication Critical patent/IT1255039B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ITRM920165A 1992-03-11 1992-03-11 Impiego di l-carnitina nel trattamento di pazienti hiv-sieropositivi presentanti deficit di carnitina. IT1255039B (it)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ITRM920165A IT1255039B (it) 1992-03-11 1992-03-11 Impiego di l-carnitina nel trattamento di pazienti hiv-sieropositivi presentanti deficit di carnitina.
EP93103740A EP0560275A1 (en) 1992-03-11 1993-03-09 Use of L-carnitine for treating carnitine-depleted HIV-seropositive patients
ZA931700A ZA931700B (en) 1992-03-11 1993-03-10 Use of L-carnitine for treating carnitine-depleted HIV-seropositive patients
KR1019930003612A KR0148350B1 (ko) 1992-03-11 1993-03-11 커르니틴 결핍 hiv-혈청 양성 환자 치료용의 l-카르니틴 함유 의약조성물
JP5050584A JPH069387A (ja) 1992-03-11 1993-03-11 カルニチン減少ｈｉｖ−漿液陽性患者の処置のためのｌ−カルニチン医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM920165A IT1255039B (it) 1992-03-11 1992-03-11 Impiego di l-carnitina nel trattamento di pazienti hiv-sieropositivi presentanti deficit di carnitina.

Publications (3)

Publication Number Publication Date
ITRM920165A0 ITRM920165A0 (it) 1992-03-11
ITRM920165A1 true ITRM920165A1 (it) 1993-09-11
IT1255039B IT1255039B (it) 1995-10-13

Family

ID=11400792

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM920165A IT1255039B (it) 1992-03-11 1992-03-11 Impiego di l-carnitina nel trattamento di pazienti hiv-sieropositivi presentanti deficit di carnitina.

Country Status (5)

Country Link
EP (1) EP0560275A1 (it)
JP (1) JPH069387A (it)
KR (1) KR0148350B1 (it)
IT (1) IT1255039B (it)
ZA (1) ZA931700B (it)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1277897B1 (it) * 1995-08-03 1997-11-12 Mendes Srl Uso della l-carnitina,di suoi derivati e di loro sali farmaceuticamen- te accettabili in combinazione con farmaci antiretrovirali per ridurre
LV13544B (en) 2005-08-15 2007-05-20 Grindeks As Pharmaceutical composition containing reverse transcriptase inhibitor and meldonium

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2921852A1 (de) * 1979-05-29 1980-12-11 Fresenius Chem Pharm Ind Lipide senkendes mittel
IT1143214B (it) * 1981-07-09 1986-10-22 Sigma Tau Ind Farmaceuti Acil derivato della carnitina quale immunomodulatore

Also Published As

Publication number Publication date
EP0560275A1 (en) 1993-09-15
JPH069387A (ja) 1994-01-18
ZA931700B (en) 1993-11-16
KR0148350B1 (ko) 1998-11-02
KR930019207A (ko) 1993-10-18
IT1255039B (it) 1995-10-13
ITRM920165A0 (it) 1992-03-11

Similar Documents

Publication Publication Date Title
IT8648358A0 (it) Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
DE69432582D1 (de) System zur Administration von Flüssigkeiten bei mehreren Patienten
NL190832C (nl) Tandbehandelingsmiddel met anti-tandsteenwerking.
FI915967L (fi) Vattenbehandlingsmedel.
DE69314334D1 (de) Vorrichtung zur osteosynthese von rückenwirbeln
FI940427A7 (fi) Ihon läpi vaikuttavia terapeuttisia systeemejä
ITRM920731A1 (it) Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
KR950700707A (ko) 치과용 치료시스템
EP0676200A3 (fr) Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales.
ITRM920165A1 (it) Impiego di l-carnitina nel trattamento di pazienti hiv-sieropositivi presentanti deficit di carnitina.
ITRM920693A0 (it) Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hiv- sieropositivi.
DE59301768D1 (de) Zahnbehandlungseinheit
FI956353L (fi) Farmaseuttiset valmisteet ja niiden käyttö etenkin neurodegeneratiivisten sairauksien hoidossa
IT8548663A0 (it) Impiego di acetil l-carnitina nel trattamento terapeutico degli statidi shock
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
ITRM910796A1 (it) Impiego di l-carnitina e acil l-carnitine nel trattamento delle oligoastenospermie idiopatiche.
FR2704394B1 (fr) Complément nutritionnel absorbable pour le traitement des cheveux et des ongles.
FI953622A0 (fi) Ifenprodiilin ja sen diastereoisomeerien käyttö lääkeaineiden valmistukseen, jotka lääkeaineet ovat käyttökelpoisia perifeeristen neuropatiatilojen ja keskushermoston degeneratiivisten sairauksien hoitoon
IT1235442B (it) Procedimento ed impianto per la disinfezione di impianti idrosanitari in particolare per idromassaggio
IT8248421A0 (it) Impiego di l-carnitina e di acil-lcarnitine nel trattamento terapeutico delle neoplasie
IT9047677A1 (it) Impiego di l-carnitina nel trattamento delle miopatie funzionali laringee.
FI972637A0 (fi) K-ryhmän vitamiinin käyttö lisäkilpirauhasen liikatoiminnan hoitoon
IT1230316B (it) Area di trattamento dentistico.
ZA927100B (en) The use of L-carnitine in endangered pregnacy.
ITRM930440A0 (it) Impiego di l-carnitina o acil l-carnitine e valproato nel trattamento dei disordini convulsivi.

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970123